Opendata, web and dolomites

mP-CSE

Micro-physiological circadian platform for safety and efficacy assessment of drugs and cosmetics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 mP-CSE project word cloud

Explore the words cloud of the mP-CSE project. It provides you a very rough idea of what is the project "mP-CSE" about.

enhances    70    schemes    physiological    risky    biotechnology    moc    dynamics    cosmetic    innovation    13    compounds    incorporation    hire    huge    time    drug    mimic    proven    companies    69    platforms    body    smart    chips    liver    ltd    single    company    3d    treatment    platform    food    chip    employees    human    scaled       heart    maximum    dose    patients    withdrawal    rhythm    adjusting    seeking       uses    cagr    5b    rate    brain    billion    roi    efficacy    medications    tissue    medicines    alternative    turn    stress    humans    reduce    predicting    sensing    organ    safe    kidney    administration    detect    tests    drugs    helping    laboratory    rhythms    global    animals    circadian    tested    animal    microphysiological    technologies    vascular    multiple    toxic    market    latest    effect    pharmaceutical    limitations    models    functionally    ultimately    costly    groundbreaking    function    precise    organs    commercialization    2025   

Project "mP-CSE" data sheet

The following table provides information about the project.

Coordinator
TISSUE DYNAMICS LTD 

Organization address
address: PARK HI-TECH, GIVAT RAM
city: JERUSALEM
postcode: 91904
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website http://www.tissuedynamics.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TISSUE DYNAMICS LTD IL (JERUSALEM) coordinator 50˙000.00

Map

 Project objective

Tissue Dynamics Ltd. is a groundbreaking biotechnology company focused on developing smart microphysiological platform technologies for drug, food, and cosmetic development. Pharmaceutical and cosmetic companies face huge costs of developing and testing new products (an average of €2.5B to develop a single drug), which is increasing over the years. Traditionally, these tests have been carried out in animal models whose limitations in predicting human responses are significant (70% of drugs toxic to humans are not toxic to animals). These limitations lead to the withdrawal of many drugs in the market, making drug development a costly risky process. Organ-on-chip platforms, developed in recent years, have proven to be a better alternative to current laboratory models, offering more physiological and similar characteristics to the human body. Tissue Dynamics goal is to provide a functionally scaled Multi Organ-on-Chip (MOC) platform that uses real-time sensing of tissue function to detect the effect of drug-induced physiological stress in multiple 3D vascular organs (liver, heart, brain, kidney). Our latest innovation has been the incorporation of factors that mimic circadian rhythms in the organs, which is essential to test the physiological impact of the compounds tested. On the other hand, the incorporation of the circadian rhythm in our chips enhances the development of treatment schemes, adjusting in a more precise way the dose and the time of administration of the medications, seeking the maximum efficacy of them. The global Organ-on-Chip market is a rapidly-growing, estimated to reach $6.13 Billion by 2025, with an expected growth rate of CAGR 69.4%. Our platform will reduce the cost of new drugs development ultimately, helping patients by making more safe and effective medicines reach the market. In turn we expect ROI of 5 after five years of commercialization and hire 10 new employees.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MP-CSE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MP-CSE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

IRMELI (2019)

AI-BASED BROKERING TECHNOLOGY PLATFORM TO FIND THE PERFECT MATCH BETWEEN THE CUSTOMER AND BANK

Read More